Tim Gallagher

Is Affymetrix 'Sequencing' A Turnaround, Or Just A Devolving Genetic Anomaly?

A trailblazing pioneer, Affymetrix (NASDAQ:AFFX) got off largely under-the-radar in 1992, and came public with its IPO in June 1996.

AFFX "blasted-off" like a rocket in the early 2000s (with over a 1500% Total Return), as it developed its DNA Chip Technology ("biochips") and integrated products, and was on the leading edge in preparing and positioning itself for The Human Genome Project, the worldwide project that completed sequencing the human gene and DNA (deoxyribonucleic acid). This led to the ongoing boom in biotechnology, big-pharma inroads, and R&D generally, and advancements in learning, as well as exponential leaps in medicine have continuously been made.

Having been professionally engaged in a career in the medicine/ healthcare field most of my...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details